Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events
JAMA · 03.10.2023 · 330 (13) · 1255
DOI: 10.1001/jama.2023.17465 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JAMA, erschienen am 03.10.2023. Verfasst von Manuel Sánchez-de-la-Torre und 17 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine in Chronic Diseases, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Department of Nursing and Physiotherapy, Fac…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Continuous Positive Airway Pressure, Sleep Apnea, Obstructive, Patient Compliance. Die Arbeit wurde bisher 238-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The effect of continuous positive airway pressure (CPAP) on secondary cardiovascular disease prevention is highly debated.
Objective
To assess the effect of CPAP treatment for obstructive sleep apnea (OSA) on the risk of adverse cardiovascular events in randomized clinical trials. Data Sources PubMed (MEDLINE), EMBASE, Current Controlled Trials: metaRegister of Controlled Trials, ISRCTN Registry, European Union clinical trials database, CENTRAL (Cochrane Central Register of Controlled Trials), and ClinicalTrials.gov databases were systematically searched through June 22, 2023. Study Selection For qualitative and individual participant data (IPD) meta-analysis, randomized clinical trials addressing the therapeutic effect of CPAP on cardiovascular outcomes and mortality in adults with cardiovascular disease and OSA were included. Data Extraction and Synthesis Two reviewers independently screened records, evaluated potentially eligible primary studies in full text, extracted data, and cross-checked errors. IPD were requested from authors of the selected studies (SAVE [ NCT00738179 ], ISAACC [ NCT01335087 ], and RICCADSA [ NCT00519597 ]). Main Outcomes and Measures One-stage and 2-stage IPD meta-analyses were completed to estimate the effect of CPAP treatment on risk of recurrent major adverse cardiac and cerebrovascular events (MACCEs) using mixed-effect Cox regression models. Additionally, an on-treatment analysis with marginal structural Cox models using inverse probability of treatment weighting was fitted to assess the effect of good adherence to CPAP (≥4 hours per day).
Results
A total of 4186 individual participants were evaluated (82.1% men; mean [SD] body mass index, 28.9 [4.5]; mean [SD] age, 61.2 [8.7] years; mean [SD] apnea-hypopnea index, 31.2 [17] events per hour; 71% with hypertension; 50.1% receiving CPAP [mean {SD} adherence, 3.1 {2.4} hours per day]; 49.9% not receiving CPAP [usual care], mean [SD] follow-up, 3.25 [1.8] years). The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]). Conclusions and Relevance Adherence to CPAP was associated with a reduced MACCE recurrence risk, suggesting that treatment adherence is a key factor in secondary cardiovascular prevention in patients with OSA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Precision Medicine in Chronic Diseases, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Department of Nursing and Physiotherapy, Faculty of Nursing and Physiotherapy, University of Lleida, Lleida, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
- Translation Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, IRBLleida, Lleida, Spain.
- Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
- Laboratorio de Inmunología Traslacional, Departamento de Bioquímica Clínica e Inmunología, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile.
- Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Sánchez-de-la-Torre, M., Gracia-Lavedan, E., Benitez, I. D., Sánchez-de-la-Torre, A., Moncusí-Moix, A., Torres, G., Loffler, K., Woodman, R., Adams, R., Labarca, G., Dreyse, J., Eulenburg, C., Thunström, E., Glantz, H., Peker, Y., Anderson, C., McEvoy, D., & Barbé, F. (2023). Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events. JAMA, 330(13), 1255. https://doi.org/10.1001/jama.2023.17465
Vancouver
Sánchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, Sánchez-de-la-Torre A, Moncusí-Moix A, Torres G, et al. Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events. JAMA. 2023;330(13):1255. doi:10.1001/jama.2023.17465
BibTeX
@article{SnchezdelaTorre2023,
author = {Sánchez-de-la-Torre, Manuel and Gracia-Lavedan, Esther and Benitez, Ivan D and Sánchez-de-la-Torre, Alicia and Moncusí-Moix, Anna and Torres, Gerard and Loffler, Kelly and Woodman, Richard and Adams, Robert and Labarca, Gonzalo and Dreyse, Jorge and Eulenburg, Christine and Thunström, Erik and Glantz, Helena and Peker, Yüksel and Anderson, Craig and McEvoy, Doug and Barbé, Ferran},
title = {Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events},
journal = {JAMA},
year = {2023},
volume = {330},
number = {13},
pages = {1255},
doi = {10.1001/jama.2023.17465}
}
EUVIMED